The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Biologics Have Long Road Ahead to Reach FDA Approval in Pain Management
While digital medicine and neuromodulation have gathered enough clinical evidence to treat chronic pain, Timothy R. Deer, MD, president and CEO of St. Francis Hospital's Center for Pain Relief, in Charleston, WV, said regenerative therapies like platelet-rich plasma, stem cells and biologics are lagging years behind in the testing realm with a long road to go.
Pain Medicine Slowly Making Progress in Value-Based Care System
The advent of accountable care organizations, bundled payments, and other reforms under the Affordable Care Act has steered the focus of health care delivery from quantity to quality, but where exactly do pain medicine providers fit into the new value-based care model, and how can it benefit their patients?
Looking for Effective Treatment Options for Painful Diabetic Peripheral Neuropathy
March 23rd 2013Severe neuropathic pain due to diabetic peripheral neuropathy is associated with negative health impact and increased healthcare utilization, underscoring the need for the development of safe and effective treatments.
Pharmacologic Treatment Options for Partial Seizures
March 23rd 2013Study results show a novel formulation of oxcarbazepine may provide long-term seizure reduction in patients with refractory epilepsy, while a separate trial produced promising results for long-term lacosamide treatment in elderly patients with partial-onset seizures.
Frequency of Infection Doesn't Fluctuate with Teriflunomide Treatment
March 19th 2013In the Multiple Sclerosis Treatment Safety poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting, Barry Singer, a neurologist at the Missouri Baptist Medical Center, in St. Louis, and founder and director of the MS Center for Innovations in Care, and his co-authors presented an analysis of infection rates in three placebo-controlled teriflunomide studies.